Literature DB >> 2276310

Intensive insulin therapy for treatment of type I diabetes.

I B Hirsch1, R Farkas-Hirsch, J S Skyler.   

Abstract

Intensive insulin therapy is best defined as a comprehensive system of diabetes management with the patient and management team as partners. The system is directed at improvement of glycemia and patient well-being. Glycemic targets should be individually defined. Frequent self-monitoring of blood glucose, probably at least four times per day, is essential for meticulous control. The benefits include improved psychosocial functioning and the potential of lessening the risks of chronic complications of diabetes. The risks relate to problems associated with hypoglycemia, which are increased if meticulous glycemic control is sought. One of the important elements of intensive therapy is a multiple-component insulin program designed to provide effective insulinemia coinciding with each major meal and continuous basal insulinemia throughout the 24-h day. This may be achieved with continuous subcutaneous insulin infusion (CSII) or multiple injections with various insulin regimens, although CSII may offer real advantages in terms of the pharmacokinetics of insulin delivery. Other pharmacokinetic issues to be considered involve selection of injection sites, timing of premeal insulin, and mixing insulins. Many studies have shown that, albeit with effort, excellent glycemic control can be achieved by various intensive insulin-therapy regimens. The implementation of a program of intensive therapy involves patient self-management in terms of altering insulin dosages, food intake, and/or activity in an attempt to achieve the target level of glycemia selected. In motivated patients willing to embark on such a course of therapy, intensive insulin therapy can be worthwhile. It should be considered for all patients with type I (insulin-dependent) diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2276310     DOI: 10.2337/diacare.13.12.1265

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  10 in total

Review 1.  Recent developments in insulin delivery techniques. Current status and future potential.

Authors:  F P Kennedy
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

Review 2.  Glycemic control and complications of diabetes mellitus.

Authors:  I B Hirsch
Journal:  West J Med       Date:  1995-05

Review 3.  How to achieve optimal diabetic control in patients with insulin-dependent diabetes.

Authors:  S R Page; R B Tattersall
Journal:  Postgrad Med J       Date:  1994-10       Impact factor: 2.401

4.  Willingness to pay for inhaled insulin: a contingent valuation approach.

Authors:  Hamid Sadri; Linda D MacKeigan; Lawrence A Leiter; Thomas R Einarson
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 5.  [Diabetic coma. Management of diabetic ketoacidosis and nonketotic hyperosmolar coma].

Authors:  J Hensen
Journal:  Internist (Berl)       Date:  2003-10       Impact factor: 0.743

6.  Impact of injection sites for soluble insulin on glycaemic control in type 1 (insulin-dependent) diabetic patients treated with a multiple insulin injection regimen.

Authors:  J E Henriksen; M S Djurhuus; A Vaag; P Thye-Rønn; D Knudsen; O Hother-Nielsen; H Beck-Nielsen
Journal:  Diabetologia       Date:  1993-08       Impact factor: 10.122

Review 7.  Insulin-dependent (type I) diabetes mellitus.

Authors:  W Rodger
Journal:  CMAJ       Date:  1991-11-15       Impact factor: 8.262

Review 8.  Treating non-insulin-dependent diabetes. Oral agents or insulin?

Authors:  A H Shlossberg
Journal:  Can Fam Physician       Date:  1993-01       Impact factor: 3.275

Review 9.  Implantable insulin pumps and metabolic control.

Authors:  K D Hepp
Journal:  Diabetologia       Date:  1994-09       Impact factor: 10.122

10.  Quantitative-proteomic comparison of alpha and Beta cells to uncover novel targets for lineage reprogramming.

Authors:  Amit Choudhary; Kaihui Hu He; Philipp Mertins; Namrata D Udeshi; Vlado Dančík; Dina Fomina-Yadlin; Stefan Kubicek; Paul A Clemons; Stuart L Schreiber; Steven A Carr; Bridget K Wagner
Journal:  PLoS One       Date:  2014-04-23       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.